Care is prevention and prevention is care is a campaign put on by the CDC to

Care is prevention and prevention is care is a

This preview shows page 7 - 10 out of 12 pages.

prevention is care is a campaign put on by the CDC to help start the conversation regarding HIV prevention (CDC, 2018a). The campaign focuses on reducing high-risk behaviors, removing the stigma of HIV, and treatment adherence (CDC, 2018a).ReferenceArcangelo, V.P., Peterson, A.M., Wilbur, V., & Reinhold, J.A. (2017). Pharmacotherapeutics for advance practice: A practical approach (4thed.). Ambler, PA: Lippincott Williams & WilkinsCenter for Disease Control. (2018a). Prevention is care. Retrieved from: on October 17, 2018Center for Disease Control. (2018b). Estimated HIV incidence and prevalence in the United States, 2010-2015). Retrieved from: on October 17, 2018Center for Disease Control. (2018c). Ways to stop HIV stigma and discrimination. Retrieved from: on October17, 2018
Lexicomp. (2018).Tenofovir disoproxil fumarate: Drug information. Retrieved from ?search=Tenofovir%20disoproxil%20fumarate&source=panel_search_result&selectedTitle=1~93&usage_type=panel&kp_tab=drug_general&display_rank=1on October 17, 2018Panel on Antiretroviral Guidelines. (2016). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Retrieved from on October 17, 2018US Public Health Service. (2017). Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 Update: A clinical practice guideline. Retrieved from on October 17, 2018.Thank you for your post, I enjoyed reading it. The guidelines recommend that all patients testing positive for HIV, be immediately started on ART (Panel on Antiretroviral Guidelines, 2016). They actually recommend that all treatment-naïve patient be started on a combination of 2nucleoside reverse transcriptase inhibitors (NRTIs) and either an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or an enhanced protease inhibitor (PI) (Panel of Antiretroviral Guidelines, 2016). The panel recommends INSTI-based regimens as the preferred initial treatment for the majority of patients diagnosed with HIV. The 2 NRTIs and an INSTI regimen has been proven to have the least amount of side effects and ease of use and therefore is typically the first-line regimen prescribed for ART-naïve patients
(Panel of Antiretroviral Guidelines, 2016). Raltegravir (RAL) is an INSTI that works by stopping integration of the proviral gene into human DNA, through inhibiting the catalytic activity of integrase (Lexicomp, 2018). RAL was the INSTI to be approved by the FDA to treat HIV and has a minimal drug-drug interaction risk (Lexicomp, 2018).

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture